Carthera raises €30M Series C for focused ultrasound blood-brain barrier opening in glioblastoma
Summary
Paris-based Carthera secured €30M Series C led by Sofinnova Partners, with Servier and BPI France, to advance their SonoCloud transcranial focused ultrasound implant for blood-brain barrier opening in glioblastoma. Phase 2/3 SONOCAUDATE trial is ongoing across 8 European centers, and funds also support development of a non-invasive transcranial version for BBB opening without implanted transducers.
Why it matters
BBB opening for chemotherapy delivery in glioblastoma is Carthera's lead indication but the non-invasive transcranial version is the platform play — enabling BBB opening for any CNS drug without surgery. Sofinnova leading again signals continued conviction in Carthera's approach as the most clinically advanced BBB opening platform.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial